{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T13:18:13Z","timestamp":1682169493055},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/cad.0b013e3283615006","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T16:05:30Z","timestamp":1366214730000},"page":"609-616","source":"Crossref","is-referenced-by-count":1,"title":["Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells"],"prefix":"10.1097","volume":"24","author":[{"given":"Yong-Zhan","family":"Zhen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Jun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Yang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Su","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210227","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"key":"R2-7-20210227","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"R3-7-20210227","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbrc.2012.10.071","article-title":"Dll1Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.","volume":"428","author":"Xu","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"R4-7-20210227","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2012.09099.x","article-title":"Bortezomib salvage followed by a phase III study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.","volume":"157","author":"Nishihori","year":"2012","journal-title":"Br J Haematol"},{"key":"R5-7-20210227","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1600-0609.2012.01765.x","article-title":"The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.","volume":"88","author":"Richardson","year":"2012","journal-title":"Eur J Haematol"},{"key":"R6-7-20210227","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsedrefractory multiple myeloma.","volume":"30","author":"JJakubowiak","year":"2012","journal-title":"J Clin Oncol"},{"key":"R7-7-20210227","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12185-009-0340-3","article-title":"Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase.","volume":"90","author":"Zhen","year":"2009","journal-title":"Int J Hematol"},{"key":"R8-7-20210227","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/aps.2009.75","article-title":"Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice.","volume":"30","author":"Zhen","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"R9-7-20210227","first-page":"602","article-title":"Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array.","volume":"24","author":"Zhong","year":"2011","journal-title":"Biomed Environ Sci"},{"key":"R10-7-20210227","first-page":"409","article-title":"Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.","volume":"29","author":"Zhang","year":"2012","journal-title":"Int J Mol Med"},{"key":"R11-7-20210227","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s10637-010-9463-x","article-title":"Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc.","volume":"29","author":"Zhen","year":"2011","journal-title":"Invest New Drugs"},{"key":"R12-7-20210227","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/gt.2010.76","article-title":"Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM.","volume":"17","author":"Xin","year":"2010","journal-title":"Gene Ther"},{"key":"R13-7-20210227","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.4161\/cbt.8.16.8955","article-title":"Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2M checkpoint and induction of apoptosis.","volume":"8","author":"Pan","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"R14-7-20210227","first-page":"450","article-title":"Analysis of combined drug effects: a new look at a very old problem Trends.","volume":"4","author":"Chou","year":"1983","journal-title":"Pharmacol Sci"},{"key":"R15-7-20210227","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"key":"R16-7-20210227","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1476-5381.2011.01449.x","article-title":"Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-B and STAT3 regulated gene products in multiple myeloma cells.","volume":"164","author":"Kannaiyan","year":"2011","journal-title":"Br J Pharmacol"},{"key":"R17-7-20210227","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"R18-7-20210227","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res"},{"key":"R19-7-20210227","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3892\/ijo.2011.1317","article-title":"Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.","volume":"40","author":"Komatsu","year":"2012","journal-title":"Int J Oncol"},{"key":"R20-7-20210227","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/1078-0432.CCR-10-0529","article-title":"Role of CAATenhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.","volume":"16","author":"Rao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R21-7-20210227","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1158\/1535-7163.MCT-08-0391","article-title":"Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.","volume":"7","author":"Lioni","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"R22-7-20210227","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/sj.leu.2404735","article-title":"Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.","volume":"21","author":"Yan","year":"2007","journal-title":"Leukemia"},{"key":"R23-7-20210227","doi-asserted-by":"crossref","first-page":"21796","DOI":"10.1074\/jbc.M111.304626","article-title":"The pp242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)eukaryotic translation initiation factor 4E (eIF-4E)RAF pathway and activation is a mechanism of resistance.","volume":"287","author":"Hoang","year":"2012","journal-title":"J Biol Chem"},{"key":"R24-7-20210227","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1021\/jm201657x","article-title":"Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.","volume":"55","author":"Lin","year":"2012","journal-title":"J Med Chem"},{"key":"R25-7-20210227","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","article-title":"Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.","volume":"107","author":"Hideshima","year":"2006","journal-title":"Blood"},{"key":"R26-7-20210227","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2007-04-083204","article-title":"MEK12 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.","volume":"110","author":"Pei","year":"2007","journal-title":"Blood"},{"key":"R27-7-20210227","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2007-10-114348","article-title":"Targeting MEKMAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.","volume":"112","author":"Lunghi","year":"2008","journal-title":"Blood"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e3283615006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:18:21Z","timestamp":1620947901000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201307000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3283615006","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}